BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37694993)

  • 1. MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses.
    Noureddin N; Ajmera V; Bergstrom J; Bettencourt R; Huang DQ; Siddiqi H; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Nakajima A; Idilman R; Gumussoy M; Oz DK; Erden A; Loomba R
    Aliment Pharmacol Ther; 2023 Nov; 58(9):856-865. PubMed ID: 37694993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants.
    Ajmera V; Kim BK; Yang K; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Nakajima A; Idilman R; Gumussoy M; Oz DK; Erden A; Quach NE; Tu X; Zhang X; Noureddin M; Allen AM; Loomba R
    Gastroenterology; 2022 Oct; 163(4):1079-1089.e5. PubMed ID: 35788349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effects of pemafibrate on metabolic dysfunction-associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis-4 index and the magnetic resonance imaging-aspartate aminotransferase score.
    Ichikawa T; Oba H; Owada M; Watanabe K; Yoshimura T; Fuchigami A; Nakamura A
    JGH Open; 2023 Dec; 7(12):959-965. PubMed ID: 38162848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease.
    Ajmera V; Nguyen K; Tamaki N; Sharpton S; Bettencourt R; Loomba R
    Therap Adv Gastroenterol; 2022; 15():17562848221093869. PubMed ID: 35509420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality.
    Lee SW; Huang DQ; Bettencourt R; Ajmera V; Tincopa M; Noureddin N; Amangurbanova M; Siddiqi H; Madamba E; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Nakajima A; Yoneda M; Idilman R; Gumussoy M; Oz DK; Erden A; Loomba R
    Aliment Pharmacol Ther; 2024 Jan; 59(1):80-88. PubMed ID: 37968251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.
    Kim BK; Tamaki N; Imajo K; Yoneda M; Sutter N; Jung J; Lin T; Tu XM; Bergstrom J; Nguyen K; Nguyen L; Le T; Madamba E; Richards L; Valasek MA; Behling C; Sirlin CB; Nakajima A; Loomba R
    J Hepatol; 2022 Dec; 77(6):1482-1490. PubMed ID: 35973577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction-associated steatohepatitis.
    Qi S; Wei X; Zhao J; Wei X; Guo H; Hu J; WuYun Q; Pan CQ; Zhang N; Zhang J
    J Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38686620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hip Fractures in Patients With Liver Cirrhosis: Worsening Liver Function Is Associated with Increased Mortality.
    Hundersmarck D; Groot OQ; Schuijt HJ; Hietbrink F; Leenen LPH; Heng M
    Clin Orthop Relat Res; 2022 Jun; 480(6):1077-1088. PubMed ID: 34978539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Tamaki N; Imajo K; Sharpton S; Jung J; Kawamura N; Yoneda M; Valasek MA; Behling C; Sirlin CB; Nakajima A; Loomba R
    Hepatology; 2022 Mar; 75(3):661-672. PubMed ID: 34496054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
    Castera L; Garteiser P; Laouenan C; Vidal-Trécan T; Vallet-Pichard A; Manchon P; Paradis V; Czernichow S; Roulot D; Larger E; Pol S; Bedossa P; Correas JM; Valla D; Gautier JF; Van Beers BE;
    J Hepatol; 2024 Mar; ():. PubMed ID: 38548067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
    Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
    Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study.
    Kim BK; Bergstrom J; Loomba R; Tamaki N; Izumi N; Nakajima A; Idilman R; Gumussoy M; Oz DK; Erden A; Truong E; Yang JD; Noureddin M; Allen AM; Loomba R; Ajmera V
    Hepatology; 2023 Dec; 78(6):1858-1866. PubMed ID: 37203233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis.
    Huang DQ; Noureddin N; Ajmera V; Amangurbanova M; Bettencourt R; Truong E; Gidener T; Siddiqi H; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Yoneda M; Nakajima A; Idilman R; Gumussoy M; Oz DK; Erden A; Allen AM; Noureddin M; Loomba R
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):829-836. PubMed ID: 37419133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.
    Lin H; Lee HW; Yip TC; Tsochatzis E; Petta S; Bugianesi E; Yoneda M; Zheng MH; Hagström H; Boursier J; Calleja JL; Goh GB; Chan WK; Gallego-Durán R; Sanyal AJ; de Lédinghen V; Newsome PN; Fan JG; Castéra L; Lai M; Harrison SA; Fournier-Poizat C; Wong GL; Pennisi G; Armandi A; Nakajima A; Liu WY; Shang Y; de Saint-Loup M; Llop E; Teh KK; Lara-Romero C; Asgharpour A; Mahgoub S; Chan MS; Canivet CM; Romero-Gomez M; Kim SU; Wong VW;
    JAMA; 2024 Apr; 331(15):1287-1297. PubMed ID: 38512249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Liver Stiffness, Measured by Magnetic Resonance Elastography, Associated With Hepatic Decompensation in Patients With Primary Sclerosing Cholangitis.
    Eaton JE; Sen A; Hoodeshenas S; Schleck CD; Harmsen WS; Gores GJ; LaRusso NF; Gossard AA; Lazaridis KN; Venkatesh SK
    Clin Gastroenterol Hepatol; 2020 Jun; 18(7):1576-1583.e1. PubMed ID: 31683058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis.
    Dallio M; Romeo M; Vaia P; Auletta S; Mammone S; Cipullo M; Sapio L; Ragone A; Niosi M; Naviglio S; Federico A
    World J Gastroenterol; 2024 Feb; 30(7):685-704. PubMed ID: 38515952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B.
    Chon YE; Jung ES; Park JY; Kim DY; Ahn SH; Han KH; Chon CY; Jung KS; Kim SU
    J Clin Gastroenterol; 2012 Jul; 46(6):518-25. PubMed ID: 22688146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease.
    Noureddin N; Huang DQ; Bettencourt R; Siddiqi H; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Nakajima A; Idilman R; Gumussoy M; Oz DK; Erden A; Gidener T; Allen AM; Ajmera V; Loomba R
    Aliment Pharmacol Ther; 2024 Jun; 59(12):1521-1526. PubMed ID: 38571305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk assessment of development of hepatic decompensation in histologically proven hepatitis B viral cirrhosis using liver stiffness measurement.
    Kim BK; Park YN; Kim DY; Park JY; Chon CY; Han KH; Ahn SH
    Digestion; 2012; 85(3):219-27. PubMed ID: 22414567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
    Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.